6th Annual Pharmaceutical and Life Sciences Conference 2024 by CII
India's top scientists and industry leaders are advocating for significant changes in the country's biotechnology and pharmaceutical sectors to ensure quicker responses to future outbreaks and drive the next industrial revolution.
Dr. Vinod K. Paul, Member of NITI Aayog, is focusing on pandemic preparedness through collaboration across government, industry, and research ecosystems. He is advocating for a "100-day mission" model, pre-approved vaccine pipelines, and international collaboration to ensure quicker response times for future outbreaks.
Dr. Rajeev Singh Raghuvanshi, Drugs Controller General of India, is pushing for regulatory improvements to speed up drug approvals, particularly for biologics and innovative therapies. He also emphasizes the importance of continuous innovation and industrial capabilities, including the manufacturing of vaccines across multiple platforms, to ensure India remains self-reliant in future health crises. He recommends the Government publish a list of priority vaccines to align innovation efforts with public health needs and support the expansion of the Universal Immunization Program.
The CDSCO has already made strides in this direction, introducing an online system that has reduced drug approval times from 20-60 days to under 3 days.
Dr. Raghuvanshi also emphasizes accepting clinical data from select countries reduces the need for repeated trials, helping India grow as a global hub for pharmaceutical innovation.
Dr. Jain, on the other hand, calls for the integration of AI, machine learning, and big data analytics into biotechnology research. This move is aimed at accelerating research and development (R&D) and ensuring India's leadership in healthcare and innovation on the world stage.
The institution driving the support for the growth of bioeconomy in India and promoting biotechnology development for the next industrial revolution in India is not explicitly stated, but India is recognized as a future key player in the biotechnology market due to its large market, agricultural potential, and growing bioinformatics competencies.
In line with these ambitions, the CII 6th Pharma and Life Sciences Summit 2024 showcases India's aspirations to become a global leader in biotechnology and pharmaceuticals. Dr. Rajesh Jain, Chairman of the CII National Committee on Biotechnology, calls for the pharmaceutical and biotechnology sectors to triple in size by 2047, with an aim to reach USD 300 billion.
Continued support from the Government, a focus on R&D, and regulatory reforms are key to achieving these goals and ensuring India drives the next industrial revolution through biotechnology.
Read also:
- Postpartum Period and Gestational Diabetes: Does it Persist?
- Controlled spree of Legionnaires' disease among Harlem residents ceased, city health authorities confirm; however, locals push for increased openness and information disclosure
- Transform City for the Better
- Prostate Cancer Examination Guidelines, Outcomes, and Financial Aspects
